Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial
2021 ◽
Vol 33
(1)
◽
pp. 103-114
Keyword(s):
Phase I
◽
2008 ◽
Vol 26
(15_suppl)
◽
pp. 14521-14521
2014 ◽
Vol 20
(24)
◽
pp. 6284-6294
◽
2010 ◽
Vol 28
(15_suppl)
◽
pp. 2531-2531
◽
2011 ◽
Vol 18
(4)
◽
pp. 1092-1100
◽
2008 ◽
Vol 26
(15_suppl)
◽
pp. 2530-2530
◽